Maykin Ho

Maykin Ho is a Venture Partner at Qiming Venture Partners, where she focuses on healthcare and life sciences investments. Previously, she spent 24 years at Goldman Sachs, retiring as a Partner and serving as Advisory Director for Global Healthcare Investment Banking and co-head of US Healthcare for Global Investment Research. During her tenure, she was recognized as a top-ranked biotechnology analyst by Institutional Investor and Greenwich Associates for over 10 consecutive years. Ho currently serves on the boards of healthcare companies, including Agios Pharmaceuticals, BioMarin Pharmaceutical, FibroGen, Neumora Therapeutics, and Parexel. She completed a postdoctoral fellowship at Harvard Medical School after earning a doctorate in Microbiology and Immunology from the State University of New York Downstate Medical Center. Her career bridges over three decades of scientific research, pharmaceutical operations, and institutional finance to guide emerging biotechnology enterprises.